A diabetes medication can reduce the risk of malignant growth of the breasts in certain women, recommends another examination.
In the study, post-menopausal women with diabetes who took the drug metformin to control their glucose were 25 percent less likely to have breast disease after 11 years.
In addition, diabetic women in the study who were taking drugs other than metformin had some malignant breast growth, in contrast to and without diabetes women of a similar age. (Studies have suggested a mostly increased risk of breast malignancy in women with diabetes, but not all trials have shown that this is the case).
The study complements an evolving body of research that shows that the drug might be effective against malignant growth characteristics. Some previous research has found that women with diabetes who take the drug have fewer malignancies and pancreatic disorders. In addition, concentrates in living organisms and on cells in laboratory dishes have suggested that the drug might impede the development of disease cells.
In any case, the new investigation has shown that the drug belongs and has no reason to be affected. Further investigation is therefore expected to confirm the findings. The results of a forthcoming preliminary investigation, supported by the National Cancer Institute, will be important in providing this evidence, said Dr Iuliana Shapira, an agent at the Feinstein Institute for Medical Research in Manhasset, New York, who was not involved in the investigation. In the preliminary round, women with malignant bust growth in the early stages who do not have diabetes are randomly designated to receive either metformin or a counterfeit treatment and they are monitored for a very long time, Shapira said.
In the new study, Dr. Rowan Chlebowski of UCLA’s David Geffen School of Medicine and partners dissected data from more than 68,000 postmenopausal women interested in the continuous screening called Women’s Health Initiative and a normal screening of 11.8 years.
During the study period, 11,290 women were diagnosed with diabetes and 3,273 women were diagnosed with intrusive breast disease.
It is not satisfactory how metformin can reduce the risk of breast malignancy, but it is known that the drug extends the action of a catalyst called AMP kinase, Shapira said. This catalyst is an “energy sensor” for cells, according to Shapira, and an expansion of its movement can cause malignant cells to bite the dust by triggering cell self-destruction.
Metformin is not clearly recommended for people with diabetes. It is also given to women with a condition known as polycystic ovarian disorder. One aim of future research is to see if the drug can be given to women at risk of developing malignant breast disease to help prevent infection, Shapira said.
The study was distributed in the Journal of Clinical Oncology on 11 June.
Distribution: Taking metformin is associated with a reduced risk of malignant growth of the breast.
Follow Rachael Rettner on Twitter @ RachaelRettner or MyHealthNewsDaily @MyHealth_MHND We are also on Facebook and Google+.